Journal of Clinical Oncology
Articles in this Issue
Treatment with programmed cell death 1/programmed cell death ligand 1 inhibitors for Kaposi sarcoma: A systematic review and meta-analysis.
e14584 Background: Kaposi Sarcoma (KS) is a cutaneous tumor of angioproliferative origin induced by the human gammaherpesvirus 8 (HHV-8). For many years,...
AI-detected tumor-infiltrating lymphocytes and response to PD-1 based treatment in advanced melanoma.
9541 Background: Biomarkers to predict response to immune checkpoint inhibition (ICI)-treated melanoma are limited. This study evaluates AI-detected tumor...
Feasibility and acceptability of remote activity and patient-reported outcome monitoring in men with prostate cancer undergoing androgen deprivation therapy.
e17090 Background: ADT, a standard treatment for prostate cancer (PC), is associated with significant side effects such as fatigue, muscle loss, weight ga...
SARC044: A phase II trial of bezuclastinib in combination with sunitinib in patients with GIST who progressed on sunitinib monotherapy.
TPS11579 Background: Gastrointestinal stromal tumors (GIST) are commonly driven by mutations in the receptor tyrosine kinase KIT ....
Ethnic disparities in clinical trials for FDA-approved drugs in lung cancer: A post-COVID era analysis (2020-2024).
e13819 Background: In the post- COVID era, disparities in healthcare have become more apparent, highlighting the urgent need to address inequities in canc...
Incidence and survival trends for primary carcinomas of the liver in the pediatric and younger adult population: Fibrolamellar carcinoma, hepatocellular carcinoma, and cholangiocarcinoma.
e16251 Background: Multiple studies have shown a rise in the incidence of carcinoma among the pediatric and younger adult populations, including breast, k...
Unmasking a rare complication: Immune checkpoint inhibitors (ICIs) and Vogt-Koyanagi-Harada (VKH) syndrome.
e14667 Background: ICIs have changed the paradigm of cancer treatment, but their immune-modulating effects can lead to severe immune-related adverse event...
Analysis of socio-economic deprivation and cancer trial participation.
e13768 Background: Socio-economic deprivation is a determinant of inequities in cancer outcomes and might influence participation in clinical trials. We e...
Optimization of the iDISCO protocol for 3D reconstruction of cancer samples using light sheet microscopy.
e15086 Background: Histopathology is widely recognized as the gold standard for cancer grading and staging, forming the cornerstone of many personalized t...
The impact of lymphocyte count dynamics on the predictive value of tumor mutational burden (TMB) for immune checkpoint inhibitors (ICI) outcomes in patients (pts) with cancer.
2663 Background: TMB has become a reliable biomarker for ICI response in several cancer types, leading to the pan-cancer FDA approval of the PD-1 inhibito...
Diagnostic properties of a novel ctDNA assay for lung cancer detection.
8034 Background: Lung cancer is a devastating disease, characterized by high mortality rates and limited treatment options once it progresses to advanced...
Understanding the tolerability and toxicity profile of nivolumab in a Black population with lung cancer.
e13788 Background: Lung cancer is one of the most common cancers. It is more common in the black population and black males have the highest mortality rat...
Phase 1 study of recombinant interleukin 15 in combination with nivolumab and ipilimumab in subjects with refractory cancers.
2617 Background: Combining immune checkpoint inhibitors with cytokine therapies holds promise in cancer immunotherapy. Recombinant human interleukin-15 (r...
Analysis of early onset colorectal cancer: Implications for research and clinical practice.
3606 Background: Young onset colorectal cancer(YOCRC), diagnosed < 50 years old, presents distinct challenges, including life transitions, and psychoso...
Outcomes of advanced stage endometrial cancer by residual disease and MMR status.
e17638 Background: Mortality rates are rising in the United States from endometrial cancer with low survival in advanced stages. The RUBY and NRG GY018 tr...
Clinical outcomes in phase I trials across solid tumors and hematological malignancies.
e19014 Background: Low expectations of clinical benefit from Phase I cancer trials may hinder patient participation and delay study findings. Although pro...
Advancing sarcoma care in a developing country: Impact of centralization and long-term international collaboration.
e23328 Background: Musculoskeletal sarcomas are rare and aggressive malignancies requiring multidisciplinary care, which frequently is not available in lo...
A phase 1 dose escalation and expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma.
8089 Background: ZG006 is a unique designed T cell engager, targeting CD3 and Delta-like ligand 3 (DLL3) with two distinct DLL3 epitopes, and bridges tumo...
Nivolumab/relatlimab versus nivolumab/ipilimumab for metastatic melanoma: A retrospective, propensity-matched cohort study.
e21553 Background: Checkpoint inhibitor immunotherapy is a mainstay in the treatment of advanced melanoma. The results of the CheckMate 067 and RELATIVITY...
The CREAFORMO-004 study: A phase II study of HR070803 plus 5-fluorouracil/leucovorin and bevacizumab as second-line treatment in patients with metastatic colorectal cancer.
e15525 Background: Irinotecan-based regimens are commonly used as second-line therapy for metastatic colorectal cancer (mCRC). Irinotecan liposomes can im...
Immune landscape in lung cancer: Lymphocyte subsets as potential predictors of treatment outcomes.
e20575 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, but the lack of reliable biomarkers to p...
Association between progression-free survival and overall survival in relapsed/refractory diffuse large B-cell lymphoma in the CAR T-cell era: A surrogate endpoint analysis.
7062 Background: In lymphoid malignancies, the strength of association between progression-free survival (PFS) and overall survival (OS) varies by disease...
Minimal residual disease (MRD) test utilization in the first 6 months after initiating MRD testing in patients with colorectal cancer (CRC).
e15710 Background: With high levels of postoperative circulating tumor DNA (ctDNA) identified as a potential predictor of CRC recurrence, clinical studies...
PlP-driven exosomal breakthroughs: Advancing immune solutions for complex tumor microenvironments.
e14511 Background: The tumor microenvironment (TME) represents a critical barrier in oncology therapy due to its ability to suppress immune responses, fac...
Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research.
e16139 Background: Camrelizumab has been verified as a standard therapy for advanced esophageal squamous cell carcinoma (ESCC). This study aimed to evalua...